article Open AccessTop 1% cited
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Cancer Cell · 2005 · Vol. 7(4) · pp. 387–397
Ross L. Levine✉(Dana-Farber Cancer Institute)Martha Wadleigh(Harvard University)Jan Cools(Vlaams Instituut voor Biotechnologie)Benjamin L. Ebert(Dana-Farber Cancer Institute)Gerlinde Wernig(Harvard University)Brian J.P. Huntly(Brigham and Women's Hospital)Titus J. Boggon(Dana-Farber Cancer Institute)Iwona Włodarska(Vlaams Instituut voor Biotechnologie)Jennifer Clark(Harvard University)Sandra Moore(Harvard University)Jennifer Adelsperger(Brigham and Women's Hospital)Sumin Koo(Brigham and Women's Hospital)Jeffrey C. Lee(Broad Institute)Stacey Gabriel(Broad Institute)Thomas Mercher(Brigham and Women's Hospital)Alan D. D’Andrea(Dana-Farber Cancer Institute)Stefan Fröhling(Harvard University)Konstanze Döhner(University Hospital Ulm)Peter Marynen(KU Leuven)Peter Vandenberghe(Vlaams Instituut voor Biotechnologie)Ruben A. Mesa(Mayo Clinic)Ayalew Tefferi(Mayo Clinic)James D. Griffin(Harvard University)Michael J. Eck(Dana-Farber Cancer Institute)William R. Sellers(Broad Institute)Matthew Meyerson(Dana-Farber Cancer Institute)Todd R. Golub(Broad Institute)Stephanie J. Lee(Harvard University)D. Gary Gilliland(Brigham and Women's Hospital)
Myeloproliferative Neoplasms: Diagnosis and TreatmentEosinophilic Disorders and SyndromesChronic Myeloid Leukemia TreatmentsEssential thrombocythemiaMyelofibrosisPolycythemia veraMyeloidBiologyMissense mutationCancer researchMutationMyeloproliferative neoplasmTyrosine kinase
MeSH terms
AdultAgedAged, 80 and overEnzyme ActivationFemaleGenotypeGranulocytesHeterozygoteHomozygoteHumansMaleMiddle AgedMitosisModels, MolecularMouth Mucosa
Citations
2,972
FWCI
99.10
field-weighted impact
References
51
Percentile
100%
vs. same field & year
Citations per year
Cited by
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
Blood · 2009 · 4,394 citations
“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
Frontiers in Oncology · 2018 · 379 citations
The molecular details of cytokine signaling via the JAK/STAT pathway
Protein Science · 2018 · 871 citations
Janus kinases in immune cell signaling
Immunological Reviews · 2009 · 1,132 citations
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
Leukemia · 2007 · 992 citations
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
Leukemia · 2009 · 418 citations
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
PLoS Medicine · 2006 · 1,402 citations
References
Can Comorbidity Be Measured By Questionnaire Rather than Medical Record Review?
Medical Care · 1996 · 1,035 citations
Photochemical preparation of a pyridone containing tetracycle: A jak protein kinase inhibitor
Bioorganic & Medicinal Chemistry Letters · 2002 · 268 citations
The Protein Kinase Complement of the Human Genome
Science · 2002 · 8,071 citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine · 2004 · 11,455 citations
SWISS-MODEL: an automated protein homology-modeling server
Nucleic Acids Research · 2003 · 5,602 citations
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Science · 2004 · 9,380 citations
A 12-Item Short-Form Health Survey
Medical Care · 1996 · 16,925 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.